What is Dysgeusia?
Dysgeusia is an altered or distorted sense of taste, characterized by abnormal taste perceptions such as metallic, bitter, sweet, or sour sensations that occur without appropriate stimuli. 1
Definition and Clinical Characteristics
Dysgeusia represents a qualitative gustatory impairment where patients experience unpleasant or distorted taste sensations. The condition differs from ageusia (complete loss of taste) or hypogeusia (reduced taste sensitivity). Patients typically describe:
- Metallic taste (most common)
- Persistent bitter, sweet, or sour sensations
- Unpleasant taste perceptions that occur spontaneously or with food intake 2, 1
The condition can manifest as an isolated symptom or accompany other sensory disturbances, particularly anosmia (loss of smell), since flavor perception involves both gustatory and olfactory systems 3.
Pathophysiology
Dysgeusia results from disruption at multiple levels of the gustatory pathway:
- Taste receptor dysfunction at the level of taste buds
- Damage to taste-transmitting cranial nerves (facial nerve VII, glossopharyngeal nerve IX, vagus nerve X)
- Central nervous system processing abnormalities
- Salivary dysfunction affecting taste molecule transport 4, 1
The taste system involves specialized cells in taste buds that generate signals transmitted to the central nervous system, allowing discrimination between nutritious and potentially harmful substances 4.
Common Etiologies
Medications
Dysgeusia is a well-recognized adverse effect of numerous drugs, including:
- Chemotherapeutic agents
- Angiotensin-converting enzyme (ACE) inhibitors
- Antibiotics
- Antihistamines
- Protease inhibitors (boceprevir causes dysgeusia in 37-45% of patients) 5, 6
Infections
- COVID-19: Dysgeusia affects 10-22% of hospitalized patients and up to 79.6% in some cohorts, often presenting early in disease course 7, 8, 9, 2
- Viral respiratory infections
- Oral candidiasis 10
Cancer Treatment
- Radiotherapy-induced oral mucositis: Dysgeusia develops when cumulative radiation dose reaches 30 Gy, may persist chronically after treatment completion 10
- Chemotherapy-induced mucositis: Taste alterations occur alongside mucosal damage 10
- Head and neck cancer patients show 42.7% pooled prevalence of dysgeusia 11
Systemic Conditions
- Chronic liver disease (cirrhosis, hepatitis) 12, 13
- Chronic kidney disease
- Diabetes mellitus
- Nutritional deficiencies (zinc, vitamin A) 12, 1
Inflammatory States
Inflammatory conditions carry 3.25-fold increased odds of dysgeusia, with significant associations in Alzheimer's disease, SARS-CoV-2 infection, chemotherapy exposure, and rhinosinusitis 14.
Clinical Impact
Dysgeusia severely compromises nutritional intake and quality of life. The condition leads to:
- Food aversion and reduced oral intake
- Malnutrition and unintentional weight loss (as demonstrated in cirrhotic patients losing 25 pounds over 3 months) 13
- Sarcopenia and loss of muscle mass 1
- Decreased treatment adherence when medication-induced 6, 3
- Psychological distress affecting overall well-being 2, 1
In vulnerable populations—elderly patients, those with chronic illness, cancer patients—dysgeusia-driven malnutrition accelerates functional decline and worsens underlying disease 14, 13.
Diagnostic Considerations
Evaluation involves both subjective patient reporting and objective assessment tools. The facial, glossopharyngeal, and vagus nerves mediate taste sensation and should be assessed when dysgeusia presents 1. Clinicians must:
- Obtain detailed medication history (dysgeusia often medication-related) 6
- Screen for recent viral infections, particularly COVID-19 2
- Evaluate for nutritional deficiencies (zinc, vitamin A) 12
- Assess for underlying systemic disease 1
- Consider inflammatory conditions as risk factors 14
Management Principles
Treatment targets the underlying cause:
- Medication review and adjustment when drug-induced (though dose reduction of protease inhibitors should be avoided as it promotes viral resistance) 5, 6
- Nutritional supplementation with zinc and vitamin A may improve dysgeusia by correcting deficiency states 12
- Supportive care during cancer treatment, recognizing that taste alterations typically resolve weeks after therapy completion 10
- Novel topical approaches: Compounded lozenges containing gabapentin, memantine, and monosodium glutamate showed 85% improvement in a small case series, suggesting potential for receptor-level intervention 15
Early identification and intervention are paramount, particularly in patients with chronic illness where dysgeusia-associated malnutrition compounds disease burden and accelerates decompensation 13.